Precision BioSciences, Inc.

NasdaqCM:DTIL Rapport sur les actions

Capitalisation boursière : US$184.5m

Precision BioSciences Gestion

Gestion contrôle des critères 4/4

Le PDG Precision BioSciences est Michael Amoroso, nommé en Oct2021, a un mandat de 4.58 ans. La rémunération annuelle totale est $ 2.19M, composée du salaire de 29.7% et des bonus 70.3%, y compris les actions et options de la société. détient directement 0.94% des actions de la société, d'une valeur de $ 1.74M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4 ans et 6.3 ans.

Informations clés

Michael Amoroso

Directeur général

US$2.2m

Rémunération totale

Pourcentage du salaire du PDG29.73%
Durée du mandat du directeur général4.6yrs
Propriété du PDG0.9%
Durée moyenne d'occupation des postes de direction4yrs
Durée moyenne du mandat des membres du conseil d'administration6.3yrs

Mises à jour récentes de la gestion

Recent updates

Article d’analyse • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Dec 29

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Summary Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility. Risks include potential safety events, competitive efficacy, and uncertain milestone/royalty revenue from partnered programs. Read the full article on Seeking Alpha
Article d’analyse • Aug 06

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Celebrations may be in order for Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders, with the analysts delivering...
Article d’analyse • Jun 23

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shares have had a horrible month, losing 29% after a relatively good period...
Article d’analyse • Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse • Dec 08

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Sep 02

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences promoted Cindy Atwell to chief business officer and carried out other leadership changes. Atwell, who was serving as senior vice president of Business Development and Alliance Management, will continue to oversee the Business Development and Alliance functions with added responsibility for Project and Portfolio Management, the company said in a Sept. 2 press release. Jeff Smith, co-founder and formerly chief technology officer, was promoted to chief research officer and will assume responsibility for the management and direction of the company’s research programs and report directly to the CEO Michael Amoroso. Precision added that Derek Jantz, co-founder and chief scientific officer, will step down from the board to focus his time partnering with Amoroso in making company strategy and managing relationships with external stakeholders. Jantz departure would reduces the number of management members serving on the board, the company added. DTIL +1.27% to $1.60 premarket Sept. 1
Seeking Alpha • Aug 16

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

PBCAR0191 is being explored in a phase 1/2 study in patients with relapsed/refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-Hodgkin's Lymphoma and PBCAR269A for multiple myeloma are expected before end of 2022. Precision has established several partners for use of its ARCUS in vivo gene editing platform; these partners are Eli Lilly, Novartis and iEcure. Company has enough cash to fund its operations until the end of 2024, giving plenty of cash runway for the foreseeable future. Precision BioSciences, Inc. (DTIL) is a great speculative biotech play to look into. That's because it is advancing an allogeneic CAR-T pipeline, along with an in vivo gene editing pipeline. Speaking of its CAR-T treatments, the main one in the pipeline would be PBCAR0191, which is being explored in a phase 1/2 study in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. In the most recent interim update, it noted that relapsed patients given this CAR T were able to achieve a 100% response rate. Why I believe it may have some potential upside is because Precision expects to release updated results from this very same study before the end of 2022. In addition, it has a pretty solid pipeline when it comes to in vivo gene editing as well. It has several wholly owned treatments and then it has many others which have already been partnered with a few pharmaceutical companies. With proof of concept established using PBCAR0191 for the treatment of patients with relapsed/refractory NHL B-cell ALL, plus an update on data from the phase 1/2 study expected before the end of 2022, these are the reasons why I believe that Precision Biosciences is a great speculative biotech play to look into. PBCAR0191 For Treatment Of Patients With Non-Hodgkin's Lymphoma And B-Cell Acute Lymphoblastic Leukemia The main program to go over involves the use of PBCAR0191, which is being developed for the treatment of patients with non-Hodgkin's lymphoma ((NHL)) and B-Cell Acute Lymphoblastic Leukemia (B-ALL). Lymphoma is cancer that develops in the lymphatic system, which is the body's fighting immune system network. The lymphatic system is composed of: Lymph Nodes, spleen, thymus gland and bone marrow area. This type of cancer affects these organs and several others. There are two main types of lymphomas that you are likely aware of, which are: Hodgkin's Lymphoma Non-Hodgkin's Lymphoma These are the two main ones, although there are some other types. Both of these types are lymphomas that have problems with the B-cells in the body, which are responsible for fighting off infections in a person's body. The main difference is found under a microscope where each of the cells are shown to be different. This is not the only difference between Hodgkin's and Non-Hodgkin's lymphoma. Hodgkin's Lymphoma is a rare type of lymphoma and only about 8,500 cases diagnosed in 2016. This compares to Non-Hodgkin's Lymphoma which had 72,500 cases were diagnosed in 2016 and is the seventh most diagnosed type of cancer. In addition, there is a difference in 5-year survival rates, which are shown directly below: Hodgkin's Lymphoma - More than 86% of patients diagnosed with this type of cancer survive 5 years or more Non-Hodgkin's Lymphoma - More than 70% of patients diagnosed with this type of cancer survive 5 years or more The main thing is that a majority of biotechs targeting the large non-Hodgkin's lymphoma market. That's because the global Non-Hodgkin's Lymphoma market is expected to reach $12.5 billion by 2027. This is a very large market opportunity for Precision Biosciences. The use of PBCAR0191 is being explored in an ongoing phase 1/2a study, which demonstrated that it could achieve high response rates in patients who relapsed after CAR T. This trial is an open-label, dose-escalation and dose expansion study to evaluate safety and efficacy of PBCAR0191 in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. Speaking of dose level and dose expansions, it is expected that Precision Biosciences could reach up to 6 dose levels total. What I will show below is that the biotech was able to achieve high response rates in a very sick patient population. How sick? Well consider that these are CAR T relapsed patients who received on average 5 prior lines of treatments. That means they gone through and failed multiple types of treatments, along with other CAR T, before entering this particular study. The positive results released as an update in June of 2022 layout the most recent dose levels which were used for this study. These dose levels used for PBCAR0191 were dose level 3 (DL3) with enhanced lymphodepletion (treatment to kill existing T-cells to make room for new ones) in 6 patients and then dose level 4 (DL4b) with reduced/decreasing lymphodepletion in another 6 patients (This dose level is referred to as the "New Cohort" or latest cohort as of January 2022). As of the May 31, 2022 cutoff date, the breakdown for each dose level cohort noted directly above is as follows: It noted that 11 out of 11 (100%) of patients achieved an objective response rate (ORR) It was said that 8 out of 11 patients achieved a complete response rate 6 patients from the pool of 11 patients remain with an ongoing response for 18 months + The data for which I highlighted above deals with both dose level cohorts (DL3 and DL4b). However, what I find intriguing is that the dose level 4b cohort (new cohort), had shown to be superior over dose level 3. This was even achieved with a reduction of lymphodepletion as well, which is always good for safety in the end. This is good news for Precision Biosciences, because it is targeting a huge unmet need. These are patients with aggressive lymphomas who fail on autologous CAR Ts and other therapies. There is no approved standard of care ((SOC)) for these patients and their progression-free survival for the time being is a mere 2 months. As far as a catalyst goes, there will be an update on the use of PBCAR0191 for the treatment of patients with relapsed/refractory NHL towards the end of 2022. In addition, to updates on the other CAR Ts in the pipeline which are PBCAR19B and PBCAR269A, which are being developed for the treatment of patients with NHL and Multiple Myeloma ((MM)) respectively. It will likely be an update on data and maybe even plans for the next study. The biotech intends to meet with the FDA to discuss the data observed and then see what it needs to do next to advance it. The hope is that it can continue to reduce the amount of lymphodepletion patients need with treating their aggressive lymphomas. This could both improve safety and efficacy of PBCAR0191. Two Massive Partnerships Worth Billions Of Dollars In Potential Milestone Payments The thing is that Precision Biosciences uses its ARCUS gene editing technology for its pipeline. It remains to be seen how well it does when it is actually utilized in humans, however, it has already attracted the attention of several pharmaceutical companies. One of the most recent partnerships for licensing the ARCUS in vivo gene editing technology involves Novartis (NVS). Novartis wanted to enter this deal to get its hands on the ARCUS gene editing technology. Precision Biosciences received an upfront payment of $75 million. That's a good start to help fund its operations, but the real deal happens if it can meet all of its milestones and earn up to $1.4 billion in cash. Of course, should any product reach the market it will obtain the usual tiered royalties on sales. Its main job will be to develop a single ARCUS nuclease that is safe and efficient for In Vivo gene insertion. The goal is to attempt to develop cures for large markets like sickle cell disease and beta thalassemia. The thalassemia market is expected to reach $3.53 billion in 2022. On the other hand, the other market opportunity is much larger. It is expected that the sickle-cell disease market will reach $5.5 billion in 2023. These are the initial indications for which Novartis wants to happen. I believe that an in vivo ARCUS nuclease will be developed. The test is whether or not such a product is efficient when it delivered to humans in a phase 1 study. These indications are just the start of what is possible. That's because the partnership could eventually expand to other hemoglobinopathies that exist out there.

Analyse de la rémunération des PDG

Comment la rémunération de Michael Amoroso a-t-elle évolué par rapport aux bénéfices de Precision BioSciences?
DateRémunération totaleSalaireBénéfices de l'entreprise
Mar 31 2026n/an/a

-US$44m

Dec 31 2025US$2mUS$651k

-US$47m

Sep 30 2025n/an/a

-US$84m

Jun 30 2025n/an/a

-US$78m

Mar 31 2025n/an/a

-US$22m

Dec 31 2024US$4mUS$635k

US$7m

Sep 30 2024n/an/a

US$11m

Jun 30 2024n/an/a

US$16m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$2mUS$630k

-US$43m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$4mUS$604k

-US$73m

Sep 30 2022n/an/a

-US$76m

Jun 30 2022n/an/a

-US$93m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$6mUS$127k

-US$31m

Rémunération vs marché: La rémunération totale de Michael ($USD 2.19M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 1.72M ).

Rémunération et revenus: La rémunération de Michael a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Michael Amoroso (47 yo)

4.6yrs
Titularisation
US$2,189,467
Compensation

Mr. Michael Amoroso is Chairman of Abeona Therapeutics LLC. Mr. Amoroso serves as Director, President and Chief Executive Officer of Precision BioSciences, Inc. since October 15, 2021. He serves as Directo...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Amoroso
President4.6yrsUS$2.19m0.94%
$ 1.7m
John Kelly
CFO & Principal Accounting Officer5.3yrsUS$1.13m0.49%
$ 900.1k
Dario Scimeca
General Counsel & Secretary6.9yrsUS$911.64k0.22%
$ 403.7k
Jefferson Smith
Co-Founder & Chief Research Officerno dataUS$1.45m0.50%
$ 928.5k
Cassie Gorsuch
Chief Scientific Officer1.3yrspas de donnéespas de données
Naresh Tanna
Chief of Staff to CEO & Head of Investor Relations1.6yrspas de donnéespas de données
Juli Blanche
Chief People Officer4yrspas de donnéespas de données
Cindy Atwell
Chief Development & Business Officerno datapas de donnéespas de données
Neil Leatherbury
Senior VP and Head of Chemistry3.3yrspas de donnéespas de données
4.0yrs
Durée moyenne de l'emploi
51yo
Âge moyen

Gestion expérimentée: L'équipe de direction de DTIL est considérée comme expérimentée (ancienneté moyenne 4 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Amoroso
President4.6yrsUS$2.19m0.94%
$ 1.7m
Samuel Broder
Member of Scientific Advisory Board8.3yrspas de donnéespas de données
Kenneth Anderson
Member of Scientific Advisory Board7.3yrspas de donnéespas de données
Hagop M. Kantarjian
Member of Scientific Advisory Board7.3yrspas de donnéespas de données
Raymond Schinazi
Member of Scientific Advisory Board7.3yrsUS$256.47kpas de données
Kevin Buehler
Independent Chairman6.5yrsUS$192.65k0.11%
$ 201.2k
Alan List
Clinical Consultant & Member of Scientific Advisory Board1.7yrsUS$909.97kpas de données
Geno Germano
Independent Director6.2yrsUS$173.90k0.093%
$ 170.8k
Shari Pire
Independent Director4.5yrsUS$162.40k0.054%
$ 100.3k
Melinda Brown
Independent Director4yrsUS$163.15k0.090%
$ 166.9k
Cameron Turtle
Member of Scientific Advisory Board7.3yrspas de donnéespas de données
Stanley Frankel
Independent Director5.1yrsUS$334.20k0.075%
$ 139.3k
6.3yrs
Durée moyenne de l'emploi
68yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de DTIL sont considérés comme expérimentés (ancienneté moyenne 6.3 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/22 21:27
Cours de l'action en fin de journée2026/05/22 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Precision BioSciences, Inc. est couverte par 9 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.